Pancreatic cancer is a common tumor of the gastrointestinal tract, accounting for about 8% to 10% of all gastrointestinal tumors, with high malignancy and poor prognosis. The early symptoms of pancreatic cancer are not typical, and most patients are already in the middle or late stage when they are detected. Studies have shown that early stage pancreatic cancer with tumor diameter less than 50px has better clinical treatment effect than middle and late stage patients, and its 5-year survival rate is about 31.3%. Therefore, early detection of pancreatic cancer is one of the key measures to improve the long-term survival rate of pancreatic cancer patients. Long-term follow-up of pancreatic cancer high-risk groups is beneficial for early detection of pancreatic cancer. The high-risk groups of pancreatic cancer include the following: 1. Patients older than 40 years old with non-specific symptoms in the upper abdomen. 2. Patients with family history of pancreatic cancer. 3. Patients with sudden onset diabetes mellitus, especially atypical diabetes mellitus. 4, Patients with chronic pancreatitis. 5. Intraductal papillary mucinous neoplasm is also a precancerous lesion. 6.Familial adenomatous polyposis. 7.Benign lesions with major distal gastrectomy. 8. High risk factors for pancreatic cancer include smoking, heavy alcohol consumption, and long-term exposure to harmful chemicals. Up to now, surgery is still the most basic treatment for pancreatic cancer and the only means to get a cure for the tumor. However, when pancreatic cancer is diagnosed, it is often in the middle or late stage, and lymph node and retroperitoneal nerve metastasis can occur early in pancreatic cancer, so its curative surgical resection rate is low. Therefore, in addition to the irreplaceable role of chemotherapy in the treatment of advanced pancreatic cancer, neoadjuvant (preoperative) chemotherapy, adjuvant (postoperative) chemotherapy, combined radiotherapy and targeted therapy and other comprehensive treatment measures have become the new paradigm of pancreatic cancer treatment.